Octagon Capital Advisors LP 13F holdings
Octagon Capital Advisors LP reported 26 positions with a total reported value of $1.1B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: DNTH DIANTHUS THERAPEUTICS INC (16.5%), DFTX DEFINIUM THERAPEUTICS INC (12.7%), ABVX ABIVAX SA (12.1%), COGT COGENT BIOSCIENCES INC (8.3%), ALMS ALUMIS INC (7.3%). Against 2026-03-31 it opened 4 new positions and exited 7. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Octagon Capital Advisors LP files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 26 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| DNTH DIANTHUS THERAPEUTICS INC | 1,841,667 | $179.5M | 16.5% |
| DFTX DEFINIUM THERAPEUTICS INC | 2,950,000 | $138.8M | 12.7% |
| ABVX ABIVAX SA | 993,000 | $132.3M | 12.1% |
| COGT COGENT BIOSCIENCES INC | 2,350,000 | $90.9M | 8.3% |
| ALMS ALUMIS INC | 2,830,700 | $79.7M | 7.3% |
| AVBP ARRIVENT BIOPHARMA INC | 1,971,054 | $68.5M | 6.3% |
| TSHA TAYSHA GENE THERAPIES INC | 9,693,244 | $66.0M | 6.1% |
| BIOA BIOAGE LABS INC | 1,748,000 | $42.8M | 3.9% |
| MIRM MIRUM PHARMACEUTICALS INC | 338,900 | $39.7M | 3.6% |
| KYMR KYMERA THERAPEUTICS INC | 310,000 | $35.5M | 3.3% |
| AKTS AKTIS ONCOLOGY INC | 960,847 | $31.0M | 2.8% |
| XENE XENON PHARMACEUTICALS INC | 490,000 | $29.6M | 2.7% |
| PALI PALISADE BIO INC | 10,276,317 | $21.5M | 2.0% |
| OCUL OCULAR THERAPEUTIX INC | 2,075,000 | $20.4M | 1.9% |
| IRON DISC MEDICINE INC | 270,000 | $19.7M | 1.8% |
| SMMT SUMMIT THERAPEUTICS INC | 1,250,000 | $18.2M | 1.7% |
| PHVS PHARVARIS N V | 456,721 | $15.8M | 1.4% |
| ANL ADLAI NORTYE LTD | 934,716 | $10.7M | 1.0% |
| DTIL PRECISION BIOSCIENCES INC | 1,350,000 | $10.6M | 1.0% |
| DBVT DBV TECHNOLOGIES S A | 574,200 | $9.4M | 0.9% |
| FTH FAETH THERAPEUTICS INC | 361,010 | $9.0M | 0.8% |
| GYRE GYRE THERAPEUTICS INC | 954,416 | $6.3M | 0.6% |
| TRVI TREVI THERAPEUTICS INC | 315,000 | $5.9M | 0.5% |
| UNCY UNICYCIVE THERAPEUTICS INC | 1,000,000 | $4.7M | 0.4% |
| CNTX CONTEXT THERAPEUTICS INC | 3,050,000 | $1.7M | 0.2% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 4 in all · reported value as of 2026-06-30
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 7 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| CENTESSA PHARMACEUTICALS PLC | 750,000 | $29.8M | 3.3% |
| KALVISTA PHARMACEUTICALS INC | 1,450,000 | $29.2M | 3.2% |
| TERNS PHARMACEUTICALS INC | 530,000 | $27.9M | 3.1% |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 719,000 | $6.4M | 0.7% |
| LXEO LEXEO THERAPEUTICS INC | 1,100,000 | $6.3M | 0.7% |
| CATX PERSPECTIVE THERAPEUTICS INC | 791,555 | $3.3M | 0.4% |
| EVMN EVOMMUNE INC | 143,472 | $3.3M | 0.4% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| ABVX ABIVAX SA | 677,000 | 993,000 | +46.7% | $132.3M |
| DFTX DEFINIUM THERAPEUTICS INC | 2,440,000 | 2,950,000 | +20.9% | $138.8M |
| PHVS PHARVARIS N V | 165,000 | 456,721 | +176.8% | $15.8M |
| TSHA TAYSHA GENE THERAPIES INC | 8,859,911 | 9,693,244 | +9.4% | $66.0M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| TRVI TREVI THERAPEUTICS INC | 1,485,000 | 315,000 | -78.8% | $5.9M |
| KYMR KYMERA THERAPEUTICS INC | 425,000 | 310,000 | -27.1% | $35.5M |
| OCUL OCULAR THERAPEUTIX INC | 3,166,600 | 2,075,000 | -34.5% | $20.4M |
| DNTH DIANTHUS THERAPEUTICS INC | 1,946,667 | 1,841,667 | -5.4% | $179.5M |
| DTIL PRECISION BIOSCIENCES INC | 2,236,732 | 1,350,000 | -39.6% | $10.6M |
| CNTX CONTEXT THERAPEUTICS INC | 5,250,000 | 3,050,000 | -41.9% | $1.7M |
CIK 1839435 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
